- Home
- NTRP vs NLSP Comparison
NTRP vs NLSP Comparison
Compare NTRP & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRP
- NLSP
- Stock Information
- Founded
- NTRP 1985
- NLSP 2015
- Country
- NTRP United States
- NLSP Switzerland
- Employees
- NTRP N/A
- NLSP N/A
- Industry
- NTRP
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- NTRP
- NLSP Health Care
- Exchange
- NTRP NYSE
- NLSP Nasdaq
- Market Cap
- NTRP 12.7M
- NLSP 12.4M
- IPO Year
- NTRP N/A
- NLSP 2021
- Fundamental
- Price
- NTRP $3.44
- NLSP $2.68
- Analyst Decision
- NTRP Hold
- NLSP
- Analyst Count
- NTRP 1
- NLSP 0
- Target Price
- NTRP $5.00
- NLSP N/A
- AVG Volume (30 Days)
- NTRP 56.6K
- NLSP 325.4K
- Earning Date
- NTRP 05-29-2025
- NLSP 07-07-2025
- Dividend Yield
- NTRP N/A
- NLSP N/A
- EPS Growth
- NTRP N/A
- NLSP N/A
- EPS
- NTRP N/A
- NLSP N/A
- Revenue
- NTRP $501,422.00
- NLSP N/A
- Revenue This Year
- NTRP $2,544.87
- NLSP N/A
- Revenue Next Year
- NTRP N/A
- NLSP N/A
- P/E Ratio
- NTRP N/A
- NLSP N/A
- Revenue Growth
- NTRP 9.30
- NLSP N/A
- 52 Week Low
- NTRP $1.39
- NLSP $1.30
- 52 Week High
- NTRP $8.50
- NLSP $16.00
- Technical
- Relative Strength Index (RSI)
- NTRP 59.00
- NLSP 62.59
- Support Level
- NTRP $3.00
- NLSP $2.19
- Resistance Level
- NTRP $4.20
- NLSP $2.54
- Average True Range (ATR)
- NTRP 0.49
- NLSP 0.19
- MACD
- NTRP 0.02
- NLSP -0.01
- Stochastic Oscillator
- NTRP 47.59
- NLSP 57.89
About NTRP NEXTTRIP INC
NextTrip Inc is a technology-driven platform delivering travel booking and travel media solutions. It provides individual and group travelers with vacations to popular and sought-after destinations in Mexico, the Caribbean, and across the world. NextTrip Media platform - Travel Magazine offers a social media platform for viewers to explore, educate, and share with friends their bucket list travel. The company is also launching an end-to-end content ecosystem that uses AI-assisted travel planning capturing advertising, building brand awareness, rewarding loyalty, and driving bookings.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.